Analyzing Salix Pharmaceuticals (SLXP) and The Competition
Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Salix Pharmaceuticals to similar businesses based on the strength of its risk, analyst recommendations, valuation, institutional ownership, dividends, earnings and profitability.
This table compares Salix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Salix Pharmaceuticals Competitors||-546.55%||-38.85%||-21.18%|
Earnings & Valuation
This table compares Salix Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Salix Pharmaceuticals Competitors||$3.02 billion||$642.98 million||-25.63|
Salix Pharmaceuticals’ rivals have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and recommmendations for Salix Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Salix Pharmaceuticals Competitors||69||333||987||29||2.69|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.67%. Given Salix Pharmaceuticals’ rivals higher possible upside, analysts plainly believe Salix Pharmaceuticals has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
66.1% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Salix Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ rivals have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.
Salix Pharmaceuticals rivals beat Salix Pharmaceuticals on 8 of the 8 factors compared.
About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Receive News & Stock Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.